Myriad Logo
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us

News Releases

May 20, 2020
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
Pipeline
May 11, 2020
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
Pipeline
Apr 20, 2020
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder
Pipeline
Apr 06, 2020
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC
Pipeline
Mar 30, 2020
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
Products
Feb 14, 2020
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy
Products
Feb 11, 2020
Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer
Pipeline
Jan 22, 2020
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer
Pipeline
Jan 21, 2020
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer
Pipeline
Jan 06, 2020
New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
Products
Dec 30, 2019
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
Pipeline
Dec 14, 2019
Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes
Pipeline
Dec 04, 2019
Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening
Pipeline
Dec 03, 2019
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Products
Nov 20, 2019
The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis
Pipeline
Previous
Next page
  • Payers
    • Overview
  • Investors
    • Investor Relations
    • Events & Presentations
    • Investor Day
  • News
    • Press Releases
    • Email Alerts Subscription
    • Myriad Genetics Blog
  • Careers
    • Joining the Team
Myriad Logo

Health. Illuminated.

  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Language Assistance
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.